Track deals, monitor catalysts, and score pipeline assets across the $15B+ epigenetic oncology market. Built for BD professionals and biotech investors.
We aggregate and normalize data from the gold standard databases in drug discovery
Genetic associations & target validation
Bioactivity data & compound metrics
Trial phases & completion dates
8-K filings & deal announcements
Everything you need to track, analyze, and act on epigenetic oncology opportunities
Every asset scored 0-100 based on biological rationale, chemistry quality, and target tractability.
70+ assets scoredReal-time notifications for FDA decisions, trial readouts, and deal announcements.
SEC 8-K integratedDeep dives into epigenetic targets with disease associations and competitive landscapes.
79 targets trackedMonitor licensing deals, acquisitions, and partnerships across the epigenetic oncology space.
Live deal feedAsk questions in natural language. Get answers grounded in our proprietary data layer.
Claude for Life SciencesTradingView charts, market caps, and stock performance for tracked companies.
Real-time dataWe're building the intelligence layer for epigenetic oncology. Join our beta program to shape the platform and get early access.
Ideal for
Phase4 Bio is a specialized intelligence platform for epigenetic oncology. We aggregate data from Open Targets, ChEMBL, ClinicalTrials.gov, and SEC EDGAR to score and track pipeline assets targeting epigenetic mechanisms in cancer.
Have more questions? Reach out to our team
Join leading BD teams and investors who are already using Phase4 Bio to track the epigenetic oncology landscape.